Aims: The main objective of the present work was to evaluate the capacity of wild mushroom extracts to potentiate the action of standard antibiotics, through synergisms that allow a decrease in their therapeutic doses and ultimately contribute to the reduction of resistances. Significance and Impact of the Study: Mushroom extracts could decrease therapeutic doses of standard antibiotics and reduce microorganism's resistance to those drugs.
Introduction
The indiscriminate use of antibiotics and chemotherapeutic agents, among other factors, has been contributing for the development of resistant species (Andrade et al. 2006 ).
For patients, antimicrobial resistance increases morbidity and mortality, while there is a significant increase in costs for health care institutions. Because of that, a huge effort has been directed towards controlling antibiotic use and raising public awareness of the need for prudent use of antibiotics (Dancer 2001; Coutinho et al. 2005) and finding new sources of active molecules.
In general, bacteria serve as host for multiple genetic elements like genes, integrons, transposons and plasmids that confer antibiotic resistance phenotypes. So, they have the genetic ability to transmit and acquire resistance to drugs that are used as therapeutic agents (Santos et al. 2011 ).
Bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and Extendedspectrum β-lactamase (ESBL)-producing Escherichia coli are microorganisms of concern with regard to multi-resistances (Calbo et al. 2006; Donskey 2006; Chambers and Deleo 2009 ). Due to this problem, there is a need to investigate new compounds or strategies to reverse this tendency in order to achieve the appropriate and effective treatment against infections by such microorganisms.
Natural matrices, in particular wild mushroom extracts emerge as interesting possibilities to be explored as antimicrobial drugs (Alves et al. 2012a) . Mushrooms are rich sources of natural antimicrobials, as they produce antibacterial and antifungal compounds to survive in their natural environment (Rathee et al. 2012) .
Additionally, it has been reported that the exposure of some food pathogens to increasing sublethal amounts of natural antimicrobials resulted in no significant global effects on the acquisition of direct tolerance, namely by L. monocytogenes, which maybe an additional advantage when compared to standard antibiotics (Luz et al. 2012 ).
In the last few years, a number of studies have been conducted in different countries to demonstrate the efficacy of natural products, not only studying their direct antimicrobial activity but also their capacity as resistance-modifying agents (Benoit-Vical et al. 2006; Singh et al. 2007) . The resistance modification is based on creating a synergistic relationship, i.e. a positive interaction created when two combined agents exert an inhibitory effect that is greater than the sum of their individual effects (Aiyegoro and Okoh 2009). It has been proven that, in addition to production of intrinsic antimicrobial compounds, plants also produce multi-drug resistance inhibitors, which enhance the activity of the antimicrobial compounds (Stermitz et al. 2000) .
According to Wagner and Ulrich-Merzenich (2009), natural extracts can provide a synergistic relationship with antibiotics, through a multi-or single-target action. A "Synergistic multi-target effect" means that the single constituents of a mono-extract or a multi-extract combination affect not only one single target, but several targets, and therefore cooperate in an agonistic, synergistic way. On the other hand, the extracts can display a mono-target action that results from the interaction of the extract with one single target. Several other authors support the mentioned idea reporting studies of synergism between natural products and antibiotics (Coutinho et al. 2008; Hemaiswarya et al. 2008; Aiyegoro and Okoh 2009; Coutinho et al. 2009; Palaniappan and Holley 2010; Braga et al. 2011; Santos et al. 2011; Mitchell et al. 2012) .
The understanding of the molecular mechanisms of synergy would tackle a new strategy for the treatment of infectious diseases, overcome drug-resistant pathogens, and reduce the use of antibiotics and consequently the side effects created by them (Hemaiswarya et al. 2008) . Each mushroom lyophilized sample (3 g) was extracted using a methanol/water (80:20; 6 centrifuged at 4000 g for 10 min and filtered through Whatman no. 4 paper. The residue was then extracted with two additional 30 mL portions of the methanol/water mixture.
Materials and methods

Mushroom species and extracts preparation
The combined extracts were evaporated at 40 °C under reduced pressure to remove methanol (rotary evaporator Büchi R-210, Flawil, Switzerland), lyophilized, redissolved in water, at a defined concentration and stored at 20 °C for further use.
Antibiotics
The antibiotics were selected according to the resistance profile of the studied bacteria:
Penicillin, Ampicillin, Amoxicillin/Clavulanic acid, Cefoxitin, Ciprofloxacin, Cotrimoxazol, Levofloxacin and were used as antibiotic (Sigma-Aldrich, St Quentin Fallavier, France).
Microorganisms
The microorganisms used were clinical isolates from patients hospitalized in various departments of the Hospital Center of Trás-os-Montes and Alto Douro -Chaves, Portugal. One Gram-positive bacteria, MRSA (resistant to beta-lactams − Penicillin Ampicillin, Cefoxitin, but also to Quinolones − Ciprofloxacin and Levofloxacin) isolated from wound exudates; and three Gram-negative bacteria with different antibiotic resistance profile: E. coli 1 (resistant to Ampicillin, Ciprofloxacin and Trimethoprim/ Sulfamethoxazole), E. coli 2 (resistant to Amoxicillin/Clavulanic acid and Ampicillin) and E. coli ESBL (resistant to Ampicillin, Nalidixic acid, Norfloxacin, Ciprofloxacin, Cephalosporins and Trimethoprim/Sulfamethoxazole) isolated from urine, were used to screen the antimicrobial activity of the mushroom extracts and antibiotics. All strains were identified using the MicroScan® panels automated methodology -Siemens (Camberley, UK). 
Bacterial susceptibility determinations
Results
Taking into account our previous findings related to antibacterial activity of wild mushrooms (Alves et al. 2012b) , the extracts that showed higher activity were selected to evaluate possible synergistic effects with different antibiotics. Fistulina hepatica Three E. coli strains with different antibiotics resistance profiles were also studied; one of them was extended-spectrum beta-lactamase-producing (ESBL).
The efficiency of Russula delica extract against E. coli (Tables 2 and 3) was higher than Leucopaxillus giganteus extract; nevertheless the latter extract showed better synergistic effects against ESBL E. coli (Table 4) . Therefore, studies should be carried out in order to clarify if Leucopaxillus giganteus inhibits β-lactamases production or may act as a beta-lactamase inhibitory compound. Among the three mushroom species, Fistulina hepatica extract gave the lowest synergistic effect against E. coli (Tables 2   and 3 ).
The action of ciprofloxacin (quinolone) was potentiated by Russula delica or
Leucopaxillus giganteus extracts (Tables 3 and 4).
Russula delica extract was the only one that gave synergistic effects with the antimetabolic antibiotic trimethoprim/sulfamethoxazole (Tables 3 and 4) . As far as we know, this is the first study reporting synergism between natural matrices and the mentioned antibiotic.
Discussion
The fight against multi-resistant bacteria is a worldwide problem of public health that should be considered in several aspects. The knowledge about the processes related to antibiotics action and resistance development, the synthesis and pharmacological The efficiency of Russula delica extract against E. coli 1 (resistant to Ampicillin, Ciprofloxacin and Trimethoprim/Sulfasoxazole) and E. coli 2 (resistant to Amoxicillin/Clavulanic acid and Ampicillin) was higher than that of Leucopaxillus giganteus extract; nevertheless the latter extract exhibited better synergistic effects against ESBL (extended-spectrum beta-lactamase-producing) E. coli. Darwish and Aburjai (2010) also described that two plants, Anagyris foetidae and Lepidium sativum, had antagonistic effect upon amoxicillin activity against a standard E. coli strain (without resistances), but conducting to synergistic effects against ESBL E. coli.
As is in the present study in which ciprofloxacin was potentiated by Leucopaxillus giganteus and Russula delica extracts, Natarajan et al. (2008) showed synergisms between Humulus lupulus extract and ciprofloxacin against E. coli, suggesting the modification of membrane permeability as possible mechanism of action.
The number of available studies regarding synergisms between natural products and β-lactamics seems to be much lower than other antibiotics (Coutinho et al. 2008; Coutinho et al. 2009; D'Arrigo et al. 2010; Braga et al. 2011; Sousa et al. 2013) .
Overall, similarly to plants, some mushroom extracts can potentiate the action of antibiotics extensively used in clinical practice for Gram-positive or Gram-negative bacteria, and might be used against multi-resistant bacteria. This is a pioneer study regarding synergistic effects between mushroom extracts and antibiotics that could allow a decrease in the therapeutic doses and a protection against increasing microorganism's resistance. Nevertheless, more studies should be conducted in order to clarify the mechanisms of action that support the observed effects upon each antibiotic and microorganism.
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